Showing 1 to 11 of 11 results
Novo Nordisk Partners with Pocketpills for Ozempic and Wegovy Home Delivery
Novo Nordisk Canada has partnered with Pocketpills, a Canadian online pharmacy, to offer home delivery of its diabetes and obesity drugs, Ozempic and Wegovy, streamlining the ordering process and providing discounts.
Novo Nordisk Partners with Pocketpills for Ozempic and Wegovy Home Delivery
Novo Nordisk Canada has partnered with Pocketpills, a Canadian online pharmacy, to offer home delivery of its diabetes and obesity drugs, Ozempic and Wegovy, streamlining the ordering process and providing discounts.
Progress
16% Bias Score
US Pharmaceutical Tariffs Threaten Drug Shortages and Higher Prices
The imminent expiration of a 90-day pause on U.S. import duties threatens to impose tariffs on imported pharmaceuticals, potentially violating WTO rules, causing higher prices for brand-name drugs and exacerbating existing generic drug shortages, especially of antibiotics and chemotherapy treatments...
US Pharmaceutical Tariffs Threaten Drug Shortages and Higher Prices
The imminent expiration of a 90-day pause on U.S. import duties threatens to impose tariffs on imported pharmaceuticals, potentially violating WTO rules, causing higher prices for brand-name drugs and exacerbating existing generic drug shortages, especially of antibiotics and chemotherapy treatments...
Progress
48% Bias Score
Trump's Pharmaceutical Tariffs Threaten Drug Shortages
President Trump's planned tariffs on pharmaceutical imports are raising concerns about drug shortages and price increases, impacting generic drug manufacturers significantly, with a 270-day investigation underway to assess national security implications.
Trump's Pharmaceutical Tariffs Threaten Drug Shortages
President Trump's planned tariffs on pharmaceutical imports are raising concerns about drug shortages and price increases, impacting generic drug manufacturers significantly, with a 270-day investigation underway to assess national security implications.
Progress
48% Bias Score
Trump Administration Averts Price Hike on Generic Drugs
The Trump administration temporarily blocked tariffs on pharmaceuticals, preventing potential price increases for millions of Americans who rely on affordable generic medications, many of which are imported from India.
Trump Administration Averts Price Hike on Generic Drugs
The Trump administration temporarily blocked tariffs on pharmaceuticals, preventing potential price increases for millions of Americans who rely on affordable generic medications, many of which are imported from India.
Progress
60% Bias Score
Trump's Pharmaceutical Tariffs: A Risky Gamble
President Trump's proposed reciprocal tariffs on pharmaceuticals, potentially effective April 2, aim to boost domestic manufacturing but risk higher drug prices and shortages in the U.S. due to increased costs and skepticism from major overseas manufacturers.
Trump's Pharmaceutical Tariffs: A Risky Gamble
President Trump's proposed reciprocal tariffs on pharmaceuticals, potentially effective April 2, aim to boost domestic manufacturing but risk higher drug prices and shortages in the U.S. due to increased costs and skepticism from major overseas manufacturers.
Progress
52% Bias Score
Teva Exceeds 2024 Expectations but 2025 Outlook Disappoints
Teva Pharmaceutical Industries reported exceeding 2024 financial results with $4.2 billion in Q4 revenue and $16.5 billion in full-year revenue; however, its share price fell almost 10% due to a less optimistic 2025 outlook of $16.8-17.4 billion in revenue and $2.35-2.65 non-GAAP EPS.
Teva Exceeds 2024 Expectations but 2025 Outlook Disappoints
Teva Pharmaceutical Industries reported exceeding 2024 financial results with $4.2 billion in Q4 revenue and $16.5 billion in full-year revenue; however, its share price fell almost 10% due to a less optimistic 2025 outlook of $16.8-17.4 billion in revenue and $2.35-2.65 non-GAAP EPS.
Progress
36% Bias Score
Pharma Companies Pledge Billions in US Manufacturing Amid Tariff Threats
Faced with potential tariffs, major US pharmaceutical companies announced over \$250 billion in domestic manufacturing expansions; however, experts doubt this will significantly reduce US reliance on foreign drug sources or lower consumer costs.
Pharma Companies Pledge Billions in US Manufacturing Amid Tariff Threats
Faced with potential tariffs, major US pharmaceutical companies announced over \$250 billion in domestic manufacturing expansions; however, experts doubt this will significantly reduce US reliance on foreign drug sources or lower consumer costs.
Progress
44% Bias Score
Trump's Executive Order Targets High Prescription Drug Prices
President Trump signed an executive order on May 12th aiming to lower U.S. prescription drug prices by tying them to the lowest prices in comparable developed countries, potentially saving Americans 50-90% on medication costs, but facing legal and implementation challenges and risking drug shortages...
Trump's Executive Order Targets High Prescription Drug Prices
President Trump signed an executive order on May 12th aiming to lower U.S. prescription drug prices by tying them to the lowest prices in comparable developed countries, potentially saving Americans 50-90% on medication costs, but facing legal and implementation challenges and risking drug shortages...
Progress
40% Bias Score
Senate Advances Six Bills to Reform Drug Patent System
The Senate Judiciary Committee advanced six bipartisan bills to reform the drug patent system, aiming to curb anti-competitive practices like "patent thickets" and "product hopping" that inflate drug prices; the legislation's success remains uncertain due to past failures.
Senate Advances Six Bills to Reform Drug Patent System
The Senate Judiciary Committee advanced six bipartisan bills to reform the drug patent system, aiming to curb anti-competitive practices like "patent thickets" and "product hopping" that inflate drug prices; the legislation's success remains uncertain due to past failures.
Progress
48% Bias Score
Generic Ozempic Approaching Canada: Potential Cost Savings and Market Disruption
Generic versions of the blockbuster weight-loss drug Ozempic could be available in Canada as early as next year, potentially slashing costs by 65 percent and increasing patient access, based on applications from at least four companies; however, the impact on public drug plans remains unclear.
Generic Ozempic Approaching Canada: Potential Cost Savings and Market Disruption
Generic versions of the blockbuster weight-loss drug Ozempic could be available in Canada as early as next year, potentially slashing costs by 65 percent and increasing patient access, based on applications from at least four companies; however, the impact on public drug plans remains unclear.
Progress
44% Bias Score
IRA's Drug Price Controls Threaten Generic Drug Market
The Inflation Reduction Act's (IRA) price negotiation provision for prescription drugs, while intending to lower costs, risks undermining the generic drug market by reducing profit incentives for generic manufacturers, potentially limiting patient access to affordable medications and decreasing inno...
IRA's Drug Price Controls Threaten Generic Drug Market
The Inflation Reduction Act's (IRA) price negotiation provision for prescription drugs, while intending to lower costs, risks undermining the generic drug market by reducing profit incentives for generic manufacturers, potentially limiting patient access to affordable medications and decreasing inno...
Progress
60% Bias Score
Showing 1 to 11 of 11 results